Navigation Links
TGen-Virginia G. Piper Cancer Center launches clinical trial for drug to treat lung cancer
Date:9/21/2011

SCOTTSDALE, Ariz. Sept. 21, 2011 Patients at Virginia G. Piper Cancer Center Clinical Trials are the first in the nation to participate in a clinical trial to determine the safety, tolerability and preliminary activity of an investigational drug that targets cell-signaling proteins associated with the most common form of lung cancer, as well as other forms of cancer such as lymphomas and neuroblastoma.

The first patient on the study was administered the first dose of AP26113 at Virginia G. Piper Cancer Center Clinical Trials, and the trial is now enrolling additional patients.

AP26113, discovered and being developed by ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA) of Cambridge, Mass., is a small molecule cancer therapy that targets the suppression of two oncogenes associated with non-small cell lung cancer (NSCLC): anaplastic lymphoma kinase (ALK), and epidermal growth factor receptor (EGFR). Oncogenes are those genes with the potential to cause cancer.

"AP26113 targets two oncogenes commonly cited in the lung cancer literature in recent years, ALK and EGFR," said Dr. Glen Weiss, the Principal Investigator for the clinical trial, a partnership of the Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

"We are the first site in the country to open a new clinical trial with AP26113, which has exciting possibilities," Dr. Weiss said of the Phase 1 and Phase 2 clinical trials planned for the drug. The Phase 1 study has just begun enrolling patients. By Phase 2, the study could include more than 100 patients at 11 clinical trial sites. "If AP26113 proves to be safe and effective, it could make a positive difference for patients with NSCLC and other cancers harboring ALK and EGFR abnormalities."

Dr. Weiss also is Director of Thoracic Oncology at Virginia G. Piper Cancer Center Clinical Trials, the partnership between TGen and Scottsdale Healthcare that treats
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. TGen, Virginia G. Piper Cancer Center studying new breast cancer drug
2. New Test Predicts Risk for Impotence After Prostate Cancer Therapy
3. Genes May Explain Blacks Bleaker Prostate Cancer Stats
4. The War on Cancer Continues
5. John Theurer Cancer Center among first clinical trial sites to join landmark MMRF study
6. MRI Can Spot Breast Cancer in High-Risk Women: Study
7. Higher Risk of Second Breast Cancer Seen in Black Women
8. 10 ways to make better decisions about cancer care
9. Costly blood clots more common than expected among cancer patients
10. Stem cells, potential source of cancer-fighting T cells
11. UNC scientist proves potential of new nanoparticle design for cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... News) -- One in five American men admits ... a new survey shows. A nationally representative ... such violence is more prevalent than diabetes. This ... slapping and hitting, kicking, biting, choking, burning or ... said. Although abuse by high-profile professional athletes ...
(Date:9/16/2014)... School of Medicine researcher Dr. Jeffrey Samet and ... recently awarded a five year, $5 million grant ... their project titled: Improving Physician Opioid Prescribing for ... are the second most commonly abused substances in ... to prescription opioids now exceed deaths from motor ...
(Date:9/16/2014)... Since the adoption of pediatric legislation, ... in line with increased investment in R&D for pediatric ... novel paediatric information and more than 130 products have ... there has been 221 changes relating to the efficacy ... old or new trials in children and 89 additions ...
(Date:9/16/2014)... testing ground, researchers at Johns Hopkins have shown that ... can substantially reduce patient wait times and possibly improve ... report on the pilot study, published online Sept. 9, ... so-called "Just-in-Time" training and inventory process used now by ... keep complicated operations from bottlenecking. , "We realized that ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 RxAnte, ... predictive analytics and targeted clinical programs, today announced ... changes support the Company’s drive to improve medication ... targeted clinical programs. On September 2, 2014, Brock ... Millennium Health, announced that RxAnte founder and President ...
Breaking Medicine News(10 mins):Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3
... Rao, an American scientist of Indian origin has been ... a new system which makes use of data for ... is the Senior Director of Engineering Research Development at ... ,Rao is reported to have contributed towards ...
... drinkers go in for wholesome and healthy food, beer drinkers ... also seen among// wine drinkers when compared to beer ... in Copenhagen have found that beer drinkers buy unhealthy food ... prefer wine, according to BBC News. ,Studying ...
... Jefferson and colleagues from Cochrane Collaboration (International private organization ... trials) reviewed data from over 50 clinical trials involving ... researchers found that the old drugs which were used ... some drugs like amantadine and rimantidine which were used ...
... employ people with Asperger's Syndrome, who suffer from difficulties ... total of 50,000 people who suffer from this disorder, ... //People who suffer from the Asperger's Syndrome have difficulty ... though the intelligence of those who suffer from this ...
... Researchers from McMaster University has reported in the Journal ... found that the scientists screened 480 strains of Streptomyces ... all the strains were multi-drug resistance //as they were ... antibiotics. ,The researchers were astonished by ...
... transmission case is due today in Harbin court today. The ... blood collected from an infected couple who sold their blood ... Northeast China. // It was found that 15 people were ... and the other four got infection indirectly from the infected, ...
Cached Medicine News:
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... present at the Sixth Annual JMP Securities Healthcare Conference on ... a.m. Pacific Time) at The St. Regis New York Hotel ... Executive Officer, is scheduled to provide a corporate overview. ...
... MINNEAPOLIS, Sept. 21, 2011 Uroplasty, Inc. (NASDAQ: ... markets innovative proprietary products to treat voiding dysfunctions, announced today ... President and CFO, will present the Company,s business strategy and ... at 2:30 PM ET on Tuesday, September 27, 2011 at ...
Cached Medicine Technology:Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 2Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 3Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: